115 results about "Adult T-cell lymphoma/leukaemia" patented technology

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The present disclosure relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4 / CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0 x 106 CAR123 T cells results in significantly delayed leukemic progression in mice. These results suggest that CD123CAR-transduced T cells may be used as an immunotherapy for the treatment of high risk AML.

The invention discloses a chimeric antigen receptor CD19-CD8H&TM-41BB-CD3zeta-mbIL15 and use thereof. The chimeric antigen receptor is formed by series connection of a heavy chain and light chain variable region (CD19scFV) of a mouse anti-human CD19 monoclonal antibody (with a cloning number being FMC63), a human CD8alpha hinge region, a transmembrane region, a human 41BB intracellular region, a human CD3zeta intracellular region and an IL15+IL15Ralphla structure. The chimeric antigen receptor is used for modifying a human T-lymphocyte, and the modified T-cell (CAR-T cell) can be used for expressing CD19 positive acute / chronic lymphocytic leukemia and treating lymphoma. The prepared CD19 mbIL15 CAR-T cell has a strong killing function on specific tumor cells.

The present disclosure relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.

The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.

This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

The invention discloses a high-throughput assay method for leukaemia driver genes. By choosing mutant genes and fusion genes commonly seen in leukaemia at present, in combination with the second-generation high-throughput sequencing technology, the method can more comprehensively assay the gene mutation and fusion conditions of leukaemia. Compared with the classical Sanger sequencing method mostlyadopted at present, the second-generation high-throughput sequencing technology has the advantages of high throughput, short sequencing time, high precision, low cost and rich information, and can accurately locate and analyze target gents in a short time. With the help of the high-throughput assay technology, the method can provide more detailed gene mutation and fusion spectra for clinical doctors to comprehensively judge the prognosis of leukaemia and guide individualized treatment.

The present invention provides an adult T cell leukemia model animal, which is a T cell function deficient animal to which a cell line infected with human T cell leukemia virus-1 is transplanted. This model animal allows the HTLV-1 infected cell line to proliferate over a long period of time, and enables not only the tumorigenesis process but also the mechanism of onset of ATL and immune response mechanism of the host against ATL to be precisely analyzed.

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

The invention discloses diterpenoid compounds, and a preparation method and application thereof. The diterpenoid compounds are prepared by the following steps: by using Aralia melanocarpa root as a raw material, carrying out extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation. The molecular formula of the compounds is C20H28O2 which is named ent-pimar-6,8(14),15-trien-19-oic acid disclosed as the structural formula in the specification. The preparation method comprises the following steps: by using the Aralia melanocarpa root as the raw material, carrying out extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation. The invention also discloses application of the diterpenoid compounds in preparing drugs for preventing and / or treating tumor and in preparing drugs for preventing and / or treating human lung adenocarcinoma, human prostatic cancer or human acute medullary system leukaemia. The diterpenoid compounds have obvious inhibiting actions when being applied to drugs for human lung adenocarcinoma, human prostatic cancer or human acute medullary system leukaemia, which indicates that the diterpenoid compounds have favorable anticancer activity and can be used as an anticancer active component or lead compound.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.

The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).